Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1626

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 17:45:14 ON 29 DEC 2008
FILE 'REGISTRY' ENTERED AT 17:45:14 ON 29 DEC 2008
COPYRIGHT (C) 2008 American Chemical Society (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.38	553.01

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.22	554.85

FILE 'REGISTRY' ENTERED AT 17:47:34 ON 29 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 DEC 2008 HIGHEST RN 1091209-49-2
DICTIONARY FILE UPDATES: 28 DEC 2008 HIGHEST RN 1091209-49-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10575790b.str





ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
6-8 11-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 11-12 13-14 13-18 14-15
15-16 16-17 17-18
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 6-8 8-9 8-12 9-10 10-11 11-12 11-13
normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom

L10 STRUCTURE UPLOADED

=> d l10
L10 HAS NO ANSWERS
L10 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l10 sss full
FULL SEARCH INITIATED 17:48:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 52309 TO ITERATE

100.0% PROCESSED 52309 ITERATIONS 9266 ANSWERS
SEARCH TIME: 00.00.01

L11 9266 SEA SSS FUL L10

=> file capl
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.82 733.67

FILE 'CAPLUS' ENTERED AT 17:48:35 ON 29 DEC 2008

FILE COVERS 1907 - 29 Dec 2008 VOL 150 ISS 1
FILE LAST UPDATED: 28 Dec 2008 (20081228/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l11 sss full
L12 751 L11

=> file reg
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 0.48 | 734.15

FILE 'REGISTRY' ENTERED AT 17:48:44 ON 29 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 DEC 2008 HIGHEST RN 1091209-49-2
DICTIONARY FILE UPDATES: 28 DEC 2008 HIGHEST RN 1091209-49-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10575790d.str





chain nodes :
19 20 21

ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
6-8 11-13 16-19 19-20 20-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 11-12 13-14 13-18 14-15
15-16 16-17 17-18
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 6-8 8-9 8-12 9-10 10-11 11-12 11-13 16-19
19-20 20-21
normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18

G1:C,N

G2:C,O,S,N,P,Hy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS
21:CLASS

L13   STRUCTURE UPLOADED

=>
Uploading C:\Program Files\STNEXP\Queries\10575790c.str





chain nodes :
19 20 21 22 23
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
6-8 11-13 16-19 19-20 20-21 21-22 21-23
ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 11-12 13-14 13-18 14-15
15-16 16-17 17-18
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 6-8 8-9 8-12 9-10 10-11 11-12 11-13 16-19
19-20 20-21
normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18 21-22 21-23

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS

L14   STRUCTURE UPLOADED

=> d l13
L13 HAS NO ANSWERS
L13   STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> d l14
L14 HAS NO ANSWERS
L14   STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s l13 sss full
FULL SEARCH INITIATED 17:51:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   36526 TO ITERATE

100.0% PROCESSED   36526 ITERATIONS   102 ANSWERS
SEARCH TIME: 00.00.02

L15   102 SEA SSS FUL L13

=> s l14 sss full
FULL SEARCH INITIATED 17:51:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   1956 TO ITERATE

100.0% PROCESSED   1956 ITERATIONS   43 ANSWERS
SEARCH TIME: 00.00.01

L16   43 SEA SSS FUL L14

=> file capl
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                         ENTRY   SESSION
FULL ESTIMATED COST   357.64   1091.79

FILE 'CAPLUS' ENTERED AT 17:51:23 ON 29 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

FILE COVERS 1907 - 29 Dec 2008 VOL 150 ISS 1
FILE LAST UPDATED: 28 Dec 2008 (20081228/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> s l15
L17         15 L15

=> s l16
L18          5 L16

=> s l17 or l18
L19         15 L17 OR L18

=> d l19 1-15 ibib hitstr
```

L19 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:770316 CAPLUS
DOCUMENT NUMBER: 149:104719
TITLE: Preparation of oxadiazole compounds as S1P receptor agonists
INVENTOR(S): Hobson, Adrian D.; Fix-Stenzel, Shannon; Cusack, Kevin P.; Breinlinger, Eric C.; Ansell, Graham K.; Stoffel, Robert H.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 150pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008076356	A1	20080626	WO 2007-US25602	20071214

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 20080280876 A1 20081113 US 2007-2196 20071214

PRIORITY APPLN. INFO.: US 2006-875251P P 20061215

OTHER SOURCE(S): MARPAT 149:104719

IT 1035214-50-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxadiazole compds. as S1P receptor agonists)

RN 1035214-50-6 CAPLUS

CN 1,2,4-Oxadiazole, 3-(4-butylphenyl)-5-(2-methylphenyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:411236 CAPLUS

DOCUMENT NUMBER: 148:403230

TITLE: Preparation of diaryloxadiazole derivatives for use as antiinflammatory and immunosuppressive agents

INVENTOR(S): Albert, Rainer; Cooke, Nigel Graham; Lewis, Ian; Weiler, Sven; Zecri, Frederic

PATENT ASSIGNEE(S): Novartis A.-G., Switz.

SOURCE: PCT Int. Appl., 35pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008037476	A1	20080403	WO 2007-EP8431	20070927

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: EP 2006-121495 A 20060929

OTHER SOURCE(S): MARPAT 148:403230

IT 1016261-23-6P 1016261-24-7P 1016261-25-8P
1016261-26-9P 1016261-27-0P 1016261-28-1P
1016261-29-2P 1016261-31-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaryloxadiazole derivs. for use as antiinflammatory and immunosuppressive agents)

RN 1016261-23-6 CAPLUS
CN Benzenepropanol, β-amino-4-[5-[2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-1,2,4-oxadiazol-3-yl]-, (βS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1016261-24-7 CAPLUS
CN Benzenepropanol, β-amino-4-[5-[2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-1,2,4-oxadiazol-3-yl]-, (βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1016261-25-8 CAPLUS
CN L-Phenylalanine, 4-[5-[2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1016261-26-9 CAPLUS
CN D-Phenylalanine, 4-[5-[2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1016261-27-0 CAPLUS
CN Benzenepropanol, β-amino-4-[5-(2-methoxy[1,1'-biphenyl]-4-yl)-1,2,4-oxadiazol-3-yl]-, (βS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1016261-28-1 CAPLUS
CN Benzenepropanol, β-amino-4-[5-(2-methoxy[1,1'-biphenyl]-4-yl)-1,2,4-oxadiazol-3-yl]-, (βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1016261-29-2 CAPLUS
CN Benzenepropanol, β-amino-4-[5-[3-methyl-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-, (βS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1016261-31-6 CAPLUS
CN Benzenepropanol, γ-amino-4-[5-[2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-1,2,4-oxadiazol-3-yl]-, (γR)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1334106 CAPLUS
DOCUMENT NUMBER: 148:11235
TITLE: Cycloalkylamino acid derivatives as sphingosine 1-phosphate receptor modulators and their preparation, pharmaceutical compositions and use in the treatment of hyperproliferative and autoimmune diseases
INVENTOR(S): Bhattacharya, Samit Kumar; Brown, Matthew Frank; Dorff, Peter Hans; La Greca, Susan Deborah; MaGuire, Robert John
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 127pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2007132307	A1	20071122	WO 2007-IB1125		20070426
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
NL 2000627	A1	20071112	NL 2007-2000627		20070504
US 20070270438	A1	20071122	US 2007-746314		20070509
PRIORITY APPLN. INFO.:			US 2006-799211P	P	20060509

OTHER SOURCE(S): MARPAT 148:11235
IT 957792-95-9P 957793-26-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of cycloalkylamino acid derivs. as sphingosine

1-phosphate receptor modulators useful in the treatment of hyperproliferative and autoimmune diseases)

RN 957792-95-9 CAPLUS

CN Cyclobutanecarboxylic acid, 3-[[[4-[3-[4-(2-methylpropyl)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]methyl]amino]-, hydrochloride (1:1), cis- (CA INDEX NAME)

Relative stereochemistry.



RN 957793-26-9 CAPLUS

CN Cyclobutanecarboxylic acid, 3-[[[4-[3-[4-(2-methylpropyl)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]methyl]amino]-, cis- (CA INDEX NAME)

Relative stereochemistry.



IT 957793-52-1P 957793-53-2P 957793-76-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of cycloalkylamino acid derivs. as sphingosine 1-phosphate receptor modulators useful in the treatment of hyperproliferative and autoimmune diseases)

RN 957793-52-1 CAPLUS

CN Benzenemethanol, 4-[3-[4-(2-methylpropyl)phenyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)



RN 957793-53-2 CAPLUS

CN Benzaldehyde, 4-[3-[4-(2-methylpropyl)phenyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)



RN 957793-76-9 CAPLUS
CN Cyclobutanecarboxylic acid, 3-[[[4-[3-[4-(2-methylpropyl)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]methyl]amino]-, ethyl ester, cis- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:81270 CAPLUS
DOCUMENT NUMBER: 146:337810
TITLE: SAR studies of 3-arylpropionic acids as potent and selective agonists of sphingosine-1-phosphate receptor-1 (S1P1) with enhanced pharmacokinetic properties
AUTHOR(S): Yan, Lin; Huo, Pei; Hale, Jeffrey J.; Mills, Sander G.; Hajdu, Richard; Keohane, Carol A.; Rosenbach, Mark J.; Milligan, James A.; Shei, Gan-Ju; Chrebet, Gary; Bergstrom, James; Card, Deborah; Mandala, Suzanne M.
CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(3), 828-831
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:337810
IT 856166-23-9P 856166-26-2P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, sphingosinephosphate receptor agonistic activity, pharmacokinetics, and structure-activity relationship of (oxadiazolylaryl)propionic acids using Heck coupling reaction)
RN 856166-23-9 CAPLUS

CN Benzenepropanoic acid, α,3-dimethyl-4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-26-2 CAPLUS
CN Benzenepropanoic acid, β,3-dimethyl-4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



IT 929202-15-3P 929202-16-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, sphingosinephosphate receptor agonistic activity, pharmacokinetics, and structure-activity relationship of (oxadiazolylaryl)propionic acids using Heck coupling reaction)
RN 929202-15-3 CAPLUS
CN Benzenepropanoic acid, α,3-dimethyl-4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 929202-16-4 CAPLUS
CN Benzenepropanoic acid, β,3-dimethyl-4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:548763 CAPLUS
DOCUMENT NUMBER: 145:180190
TITLE: Highly selective and potent agonists of sphingosine-1-phosphate 1 (S1P1) receptor
AUTHOR(S): Vachal, Petr; Toth, Leslie M.; Hale, Jeffrey J.; Yan, Lin; Mills, Sander G.; Chrebet, Gary L.; Koehane, Carol A.; Hajdu, Richard; Milligan, James A.; Rosenbach, Mark J.; Mandala, Suzanne
CORPORATE SOURCE: Department of Medicinal Chemistry, Merck & Co., Inc., Rahway, NJ, 07065, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(14), 3684-3687
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 856166-11-5P 856167-04-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(agonists of sphingosine-1-phosphate 1 receptor)
RN 856166-11-5 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-chloro-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856167-04-9 CAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:548762 CAPLUS
DOCUMENT NUMBER: 145:210970
TITLE: Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes
AUTHOR(S): Yan, Lin; Huo, Pei; Doherty, George; Toth, Lesile; Hale, Jeffrey J.; Mills, Sander G.; Hajdu, Richard; Keohane, Carol A.; Rosenbach, Mark J.; Milligan, James A.; Shei, Gan-Ju; Chrebet, Gary; Bergstrom, James; Card, Deborah; Quackenbush, Elizabeth; Wickham, Alexandra; Mandala, Suzanne M.
CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(14), 3679-3683
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:210970
IT 856166-09-1P 856166-11-5P 856166-12-6P
856166-13-7P 856166-14-8P 856166-15-9P
856166-16-0P 856166-74-0P 856166-82-0P
856166-88-6P 856166-89-7P 856166-90-0P
856167-04-9P 905308-09-0P 905308-11-4P
905308-13-6P 905308-15-8P 905308-18-1P
905308-20-5P 905308-32-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes)
RN 856166-09-1 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-11-5 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-chloro-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-12-6 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-bromo-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-13-7 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-methoxy-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-14-8 CAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[5-[3-methyl-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-15-9 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-fluoro-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-16-0 CAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[5-[5-(2-methylpropyl)-2-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-74-0 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-(1,1-difluoro-2-methylpropyl)-2-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-82-0 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(2,2,2-trifluoro-1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-88-6 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(2,2,2-trifluoroethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-89-7 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-[2,2,2-trifluoro-1-(trifluoromethyl)ethoxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-90-0 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-[(1S)-1-methylpropoxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 856167-04-9 CAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 905308-09-0 CAPLUS
CN Benzeneacetic acid, 4-[5-(4-cyclohexylphenyl)-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 905308-11-4 CAPLUS
CN Benzenepropanoic acid, 4-[5-(4-cyclohexylphenyl)-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 905308-13-6 CAPLUS
CN Benzenebutanoic acid, 4-[5-(4-cyclohexylphenyl)-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 905308-15-8 CAPLUS
CN Benzenehexanoic acid, 4-[5-(4-cyclohexylphenyl)-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 905308-18-1 CAPLUS
CN Benzenepropanoic acid, 4-[5-[4-ethoxy-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 905308-20-5 CAPLUS
CN Benzenepropanoic acid, 4-[5-[4-methoxy-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 905308-32-9 CAPLUS
CN Benzenepropanoic acid, 4-[5-(5-butyl-2-pyridinyl)-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



IT 905308-53-4P 905308-74-9P 911450-38-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes)
RN 905308-53-4 CAPLUS
CN Benzeneacetic acid, 4-[5-(4-cyclohexylphenyl)-1,2,4-oxadiazol-3-yl]-3-methyl-, ethyl ester (CA INDEX NAME)



RN 905308-74-9 CAPLUS
CN Benzenepropanoic acid, 4-[5-(5-chloro-2-pyridinyl)-1,2,4-oxadiazol-3-yl]-3-

methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 911450-38-9 CAPLUS
CN Benzenepropanoic acid, 4-[5-(4-cyclohexylphenyl)-1,2,4-oxadiazol-3-yl]-3-methyl-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:564648 CAPLUS
DOCUMENT NUMBER: 143:97368
TITLE: Preparation of five-membered heterocycle-substituted benzenepropanoic and related acids as selective S1P1 (EDG1) receptor agonists
INVENTOR(S): Colandrea, Vincent J.; Doherty, George A.; Hale, Jeffrey J.; Huo, Pei; Legiec, Irene E.; Toth, Leslie; Vachal, Petr; Yan, Lin
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 230 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058848	A1	20050630	WO 2004-US41887	20041213

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004299456	A1	20050630	AU 2004-299456		20041213
CA 2547198	A1	20050630	CA 2004-2547198		20041213
EP 1697333	A1	20060906	EP 2004-814111		20041213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS					
CN 1894225	A	20070110	CN 2004-80037208		20041213
JP 2007515432	T	20070614	JP 2006-545810		20041213
US 20080249093	A1	20081009	US 2006-575790		20060412
IN 2006DN02136	A	20070629	IN 2006-DN2136		20060419
PRIORITY APPLN. INFO.:			US 2003-530186P	P	20031217
			WO 2004-US41887	W	20041213

OTHER SOURCE(S): CASREACT 143:97368; MARPAT 143:97368

IT 856166-09-1P, 3-[4-[5-(3-Cyano-4-isopropyloxyphenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-11-5P, 3-[4-[5-(4-Isopropoxy-3-chlorophenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-12-6P, 3-[4-[5-(4-Isopropoxy-3-bromophenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-13-7P, 3-[4-[5-(4-Isopropoxy-3-methoxyphenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-14-8P, 3-[4-[5-(4-Isopropoxy-3-methylphenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-15-9P, 3-[4-[5-(4-Isopropoxy-3-fluorophenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-16-0P, 3-[4-[5-[5-(2-Methylpropyl)pyridin-2-yl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-23-9P, 2-Methyl-3-[4-[5-[3-(trifluoromethyl)-4-isopropoxyphenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-24-0P, 2-Methyl-3-[4-[5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-25-1P, 2-Methyl-3-[4-[5-(3-methyl-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-26-2P, 3-[4-[5-[3-(Trifluoromethyl)-4-isopropoxyphenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]butanoic acid 856166-27-3P, 3-[4-[5-(3-Cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]butanoic acid 856166-28-4P, 3-[4-[5-(3-Methyl-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]butanoic acid 856166-74-0P, 3-[4-[5-[5-(1,1-Difluoro-2-methylpropyl)pyridin-2-yl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-78-4P, 3-[4-[5-[4-(1,1-Difluoro-2-methylpropyl)phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-80-8P, 3-[4-[5-[3-Chloro-4-(cyclopentyloxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-81-9P, 3-[4-[5-[3-Chloro-4-(2-methylpropoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-82-0P, 3-[4-[5-[3-Cyano-4-[1-(trifluoromethyl)ethoxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-83-1P, 3-[4-[5-[3-Chloro-4-[1-(trifluoromethyl)ethoxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-84-2P, 3-[4-[5-(3,5-Dichloro-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-85-3P, 3-[4-[5-[3-Chloro-4-(cyclopropylmethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-86-4P 856166-87-5P, 3-[4-[5-[3-Nitro-4-[1-(trifluoromethyl)ethoxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-88-6P, 3-[4-[5-[3-Cyano-4-(2,2,2-trifluoroethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-89-7P, 3-[4-[5-[3-Cyano-4-[1-(trifluoromethyl)-2,2,2-trifluoroethoxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-90-0P , 3-[4-[5-[3-Cyano-4-[((S)-1-methylpropyl)oxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-92-2P,

3-[4-[5-[4-Amino-6-(2,2,2-trifluoro-1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856166-94-4P, 3-[4-[5-[3-Cyano-4-[((S)-1-methylpropyl)oxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]butanoic acid 856166-95-5P, 3-[4-[5-[3-Cyano-4-[1-(trifluoromethyl)-2,2,2-trifluoroethoxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]butanoic acid 856166-96-6P, 3-[4-[5-[3-Cyano-4-(2,2,2-trifluoroethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]butanoic acid 856167-09-4P 856167-14-1P 856167-19-6P, erythro-(±)-2,3-Dihydroxy-3-[4-[5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856167-21-0P, threo-(±)-2,3-Dihydroxy-3-[4-[5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856167-29-8P, 3-[4-[5-(3,4-Dihydro-2-methyl-2H-1-benzothiopyran-6-yl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid 856167-30-1P, 3-[4-[5-[3-Chloro-4-(isopropylthio)phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of five-membered heterocycle-substituted benzenepropanoic and related acids as selective S1P1 (EDG1) receptor agonists)

RN 856166-09-1 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-11-5 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-chloro-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-12-6 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-bromo-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-13-7 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-methoxy-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-14-8 CAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[5-[3-methyl-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-15-9 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-fluoro-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-16-0 CAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[5-[5-(2-methylpropyl)-2-pyridinyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-23-9 CAPLUS
CN Benzenepropanoic acid, α,3-dimethyl-4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-24-0 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-α,3-dimethyl- (CA INDEX NAME)



RN 856166-25-1 CAPLUS
CN Benzenepropanoic acid, α,3-dimethyl-4-[5-[3-methyl-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-26-2 CAPLUS
CN Benzenepropanoic acid, β,3-dimethyl-4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-27-3 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-β,3-dimethyl- (CA INDEX NAME)



RN 856166-28-4 CAPLUS
CN Benzenepropanoic acid, β,3-dimethyl-4-[5-[3-methyl-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-74-0 CAPLUS
CN Benzenepropanoic acid, 4-[5-[5-(1,1-difluoro-2-methylpropyl)-2-pyridinyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-78-4 CAPLUS
CN Benzenepropanoic acid, 4-[5-[4-(1,1-difluoro-2-methylpropyl)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-80-8 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-chloro-4-(cyclopentyloxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-81-9 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-chloro-4-(2-methylpropoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-82-0 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(2,2,2-trifluoro-1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-83-1 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-chloro-4-(2,2,2-trifluoro-1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-84-2 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3,5-dichloro-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-85-3 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-chloro-4-(cyclopropylmethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-86-4 CAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[5-(5-propoxy-2-pyridinyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-87-5 CAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[5-[3-nitro-4-(2,2,2-trifluoro-1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856166-88-6 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(2,2,2-trifluoroethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-89-7 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-[2,2,2-trifluoro-1-(trifluoromethyl)ethoxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-90-0 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-[(1S)-1-methylpropoxy]phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 856166-92-2 CAPLUS
CN Benzenepropanoic acid, 4-[5-[4-amino-2-(2,2,2-trifluoro-1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856166-94-4 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-[(1S)-1-methylpropoxy]phenyl]-1,2,4-oxadiazol-3-yl]-β,3-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 856166-95-5 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-[2,2,2-trifluoro-1-(trifluoromethyl)ethoxy]phenyl]-1,2,4-oxadiazol-3-yl]-β,3-dimethyl- (CA INDEX NAME)



RN 856166-96-6 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(2,2,2-trifluoroethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-β,3-dimethyl- (CA INDEX NAME)



RN 856167-09-4 CAPLUS
CN Benzenepropanoic acid, α,α-difluoro-β-hydroxy-3-methyl-4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856167-14-1 CAPLUS
CN Benzenepropanoic acid, α,α-difluoro-3-methyl-4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)



RN 856167-19-6 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-α,β-dihydroxy-3-methyl-, (αR,βR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 856167-21-0 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-α,β-dihydroxy-3-methyl-, (αR,βS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 856167-29-8 CAPLUS
CN Benzenepropanoic acid, 4-[5-(3,4-dihydro-2-methyl-2H-1-benzothiopyran-6-yl)-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



RN 856167-30-1 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-chloro-4-[(1-methylethyl)thio]phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl- (CA INDEX NAME)



IT 856166-93-3, tert-Butyl 3-[4-[5-[4-nitro-6-(2,2,2-trifluoro-1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoate
856167-26-5, Methyl threo-(±)-2,3-dihydroxy-3-[4-[5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoate
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of five-membered heterocycle-substituted benzenepropanoic and related acids as selective S1P1 (EDG1) receptor agonists)

RN 856166-93-3 CAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[5-[4-nitro-2-(2,2,2-trifluoro-1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 856167-26-5 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-α,β-dihydroxy-3-methyl-, methyl ester, (αR,βS)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 856166-10-4P, tert-Butyl 3-[4-[5-(3-cyano-4-isopropyloxyphenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoate 856166-17-1P, tert-Butyl 3-[4-[5-[5-(2-methylpropyl)pyridin-2-yl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoate 856167-11-8P, 1-[4-[5-[4-Isopropoxy-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]ethane-1,2-diol 856167-13-0P, Ethyl 2,2-difluoro-3-hydroxy-3-[4-[5-[4-isopropoxy-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoate 856167-15-2P, Ethyl 2,2-difluoro-3-[4-[5-[4-isopropoxy-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoate 856167-20-9P, Methyl erythro-(±)-2,3-dihydroxy-3-[4-[5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl]-3-methylphenyl]propanoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of five-membered heterocycle-substituted benzenepropanoic and related acids as selective S1P1 (EDG1) receptor agonists)

RN 856166-10-4 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-3-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 856166-17-1 CAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[5-[5-(2-methylpropyl)-2-pyridinyl]-1,2,4-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 856167-11-8 CAPLUS
CN 1,2-Ethanediol, 1-[3-methyl-4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]phenyl]- (CA INDEX NAME)



RN 856167-13-0 CAPLUS
CN Benzenepropanoic acid, α,α-difluoro-β-hydroxy-3-methyl-4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]-, ethyl ester (CA INDEX NAME)



RN 856167-15-2 CAPLUS
CN Benzenepropanoic acid, α,α-difluoro-3-methyl-4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]-, ethyl ester (CA INDEX NAME)



RN 856167-20-9 CAPLUS
CN Benzenepropanoic acid, 4-[5-[3-cyano-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-α,β-dihydroxy-3-methyl-, methyl ester, (αR,βR)-rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:777577 CAPLUS
DOCUMENT NUMBER: 139:286336
TITLE: Medicinal composition containing inhibitor of decomposition of extracellular matrix of cartilage
INVENTOR(S): Gemba, Takefumi; Okamoto, Hiroyuki; Watanabe, Fumihiko
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080042	A1	20031002	WO 2003-JP3673	20030326
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003221160	A1	20031008	AU 2003-221160	20030326

EP 1491190 A1 20041229 EP 2003-712957 20030326
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
US 20050227994 A1 20051013 US 2004-508530 20040921
PRIORITY APPLN. INFO.: JP 2002-87330 A 20020327
WO 2003-JP3673 W 20030326
OTHER SOURCE(S): MARPAT 139:286336
IT 372105-93-6P 372106-08-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(medicinal composition containing inhibitor of decomposition of extracellular matrix
of cartilage and preparation of said inhibitor)
RN 372105-93-6 CAPLUS
CN D-Valine, N-[[4-[3-(4-butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-08-6 CAPLUS
CN D-Phenylalanine, N-[[4-[3-(4-butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:816651 CAPLUS
DOCUMENT NUMBER: 135:358158
TITLE: Preparation of N-[4-(oxadiazol-2-yl)phenylsulfonyl]-amino acid derivatives having therapeutic or preventive efficacies against glomerular disorders
INVENTOR(S): Shinosaki, Toshihiro; Ninomiya, Mitsuyoshi; Watanabe, Fumihiko
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083464	A1	20011108	WO 2001-JP3215	20010416

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2000-120235 A 20000421
OTHER SOURCE(S): MARPAT 135:358158

IT 372105-93-6P, (R)-2-[[[4-[3-(4-Butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-isopropylethanoic acid 372105-99-2P, (R)-2-[[[4-[3-(4-Propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-isopropylethanoic acid 372106-00-8P, (S)-2-[[[4-[3-(4-Propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-isopropylethanoic acid 372106-08-6P, (R)-2-[[[4-[3-(4-Butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-benzylethanoic acid 372106-14-4P, (R)-2-[[[4-[3-(4-Propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-benzylethanoic acid 372106-15-5P, (S)-2-[[[4-[3-(4-Propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-benzylethanoic acid 372106-25-7P, (R)-2-[[[4-[3-(4-Propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-methylethanoic acid 372106-26-8P, (S)-2-[[[4-[3-(4-Propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-methylethanoic acid 372106-42-8P, 2-[[[4-[3-(4-Propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]ethanoic acid 372106-53-1P, (S)-2-[[[4-[3-(4-Propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-(3-indolylmethyl)ethanoic acid 372106-54-2P, (R)-2-[[[4-[3-(4-Butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-(3-indolylmethyl)ethanoic acid 372106-59-7P, (S)-2-[[[4-[3-(4-Propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-isobutylethanoic acid
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [(oxadiazolyl)phenylsulfonyl]-amino acid derivs. as matrix metalloproteinase inhibitors and therapeutic or preventive agents for glomerular disorders)

RN 372105-93-6 CAPLUS
CN D-Valine, N-[[4-[3-(4-butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372105-99-2 CAPLUS
CN D-Valine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-00-8 CAPLUS
CN L-Valine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-08-6 CAPLUS
CN D-Phenylalanine, N-[[4-[3-(4-butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-14-4 CAPLUS
CN D-Phenylalanine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-15-5 CAPLUS
CN L-Phenylalanine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-25-7 CAPLUS
CN D-Alanine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-26-8 CAPLUS
CN L-Alanine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-42-8 CAPLUS
CN Glycine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)



RN 372106-53-1 CAPLUS
CN L-Tryptophan, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-54-2 CAPLUS
CN D-Tryptophan, N-[[4-[3-(4-butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-59-7 CAPLUS
CN L-Leucine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:816650 CAPLUS
DOCUMENT NUMBER: 135:357931
TITLE: Preparation of oxadiazole derivatives as anticancer agents inhibiting MMP-2
INVENTOR(S): Yoshioka, Takayuki; Maekawa, Ryuji; Watanabe, Fumihiko
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083463	A1	20011108	WO 2001-JP3214	20010416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001046916	A	20011112	AU 2001-46916	20010416
CA 2406685	A1	20021017	CA 2001-2406685	20010416

CA 2406685		C	20061031			
EP 1277744		A1	20030122	EP 2001-919938		20010416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
BR 2001010211		A	20030603	BR 2001-10211		20010416
HU 2003000619		A2	20030728	HU 2003-619		20010416
HU 2003000619		A3	20060228			
AU 2001246916		B2	20041007	AU 2001-246916		20010416
CN 1199956		C	20050504	CN 2001-811240		20010416
RU 2275371		C2	20060427	RU 2002-130247		20010416
JP 3974781		B2	20070912	JP 2001-580892		20010416
ZA 2002008307		A	20031015	ZA 2002-8307		20021015
NO 2002005035		A	20021219	NO 2002-5035		20021018
NO 324868		B1	20071217			
MX 2002PA10325		A	20030425	MX 2002-PA10325		20021018
US 20030203940		A1	20031030	US 2002-257917		20021018
US 6720343		B2	20040413			
IN 2002CN01705		A	20050211	IN 2002-CN1705		20021018
KR 542780		B1	20060111	KR 2002-713969		20021018
US 20040122066		A1	20040624	US 2003-730946		20031210
PRIORITY APPLN. INFO.:				JP 2000-120234	A	20000421
				WO 2001-JP3214	W	20010416
				US 2002-257917	A3	20021018

OTHER SOURCE(S): MARPAT 135:357931

IT 372105-93-6P 372105-99-2P 372106-00-8P
372106-08-6P 372106-14-4P 372106-15-5P
372106-25-7P 372106-26-8P 372106-42-8P
372106-53-1P 372106-54-2P 372106-59-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxadiazole derivs. as anticancer agents inhibiting MMP-2)

RN 372105-93-6 CAPLUS

CN D-Valine, N-[[4-[3-(4-butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372105-99-2 CAPLUS

CN D-Valine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-00-8 CAPLUS
CN L-Valine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-08-6 CAPLUS
CN D-Phenylalanine, N-[[4-[3-(4-butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-14-4 CAPLUS
CN D-Phenylalanine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-15-5 CAPLUS
CN L-Phenylalanine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-25-7 CAPLUS
CN D-Alanine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-26-8 CAPLUS
CN L-Alanine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-42-8 CAPLUS
CN Glycine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)



RN 372106-53-1 CAPLUS
CN L-Tryptophan, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-54-2 CAPLUS
CN D-Tryptophan, N-[[4-[3-(4-butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-59-7 CAPLUS
CN L-Leucine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:753066 CAPLUS
DOCUMENT NUMBER: 135:310683
TITLE: Organic electroluminescent material, heterocyclic compound, and electroluminescent device
INVENTOR(S): Taguchi, Toshiki
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
JP 2001288172	A	20011016	JP 2000-98821		20000331
US 20020037427	A1	20020328	US 2001-820878		20010330
PRIORITY APPLN. INFO.:			JP 2000-98821	A	20000331
			JP 2000-98913	A	20000331

IT 366804-22-0
RL: DEV (Device component use); USES (Uses)
(aromatic heterocyclic compound having asym. carbon as phosphor for electroluminescent device)
RN 366804-22-0 CAPLUS
CN 1,2,4-Oxadiazole, 5,5',5''-(1,3,5-benzenetriyl)tris[3-[4-(1-methylpropyl)phenyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:826051 CAPLUS
DOCUMENT NUMBER: 124:18728
ORIGINAL REFERENCE NO.: 124:3435a,3438a
TITLE: Dependence of mesomorphic properties of 3,5-disubstituted 1,2,4-oxadiazoles on geometric and electronic factors
AUTHOR(S): Karamysheva, Liudmila A.; Torgova, Sofia I.; Agafonova, Irina F.; Shitikov, Nikolai M.
CORPORATE SOURCE: Organic Intermediates and Dyes Institute, Moscow, Russia
SOURCE: Molecular Crystals and Liquid Crystals Science and Technology, Section A: Molecular Crystals and Liquid Crystals (1995), 260, 217-25
CODEN: MCLCE9; ISSN: 1058-725X
PUBLISHER: Gordon & Breach
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 171622-08-5 171622-21-2 171622-37-0
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PROC (Process)
(effect of geometric and electronic factors on liquid crystal phase transitions of)
RN 171622-08-5 CAPLUS
CN 1,2,4-Oxadiazole, 5-(4-butoxyphenyl)-3-(4-pentylphenyl)- (CA INDEX NAME)



RN 171622-21-2 CAPLUS
CN 1,2,4-Oxadiazole, 5-(4'-pentyl[1,1'-biphenyl]-4-yl)-3-(4-pentylphenyl)- (CA INDEX NAME)



RN 171622-37-0 CAPLUS
CN 1,2,4-Oxadiazole, 5-(4-nitrophenyl)-3-(4-pentylphenyl)- (CA INDEX NAME)



L19 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:389142 CAPLUS
DOCUMENT NUMBER: 122:252686
ORIGINAL REFERENCE NO.: 122:45868h,45869a
TITLE: 3,5-Disubstituted 1,2,4-oxadiazoles-new class of liquid crystalline compounds
AUTHOR(S): Karamysheva, L. A.; Torgova, S. I.; Agafonova, I. F.; Geivandov, R. Ch.
CORPORATE SOURCE: Organic Intermediates & Dyes Inst., Moscow, 103787, Russia
SOURCE: Molecular Crystals and Liquid Crystals Science and Technology, Section C: Molecular Materials (1994), 4(4), 289-93
CODEN: MOMAEO; ISSN: 1058-7276
PUBLISHER: Gordon & Breach
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 162407-97-8P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and liquid crystal properties of)
RN 162407-97-8 CAPLUS
CN 1,2,4-Oxadiazole, 5-[4-(4-pentylcyclohexyl)phenyl]-3-(4-propylphenyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L19 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1982:527647 CAPLUS
DOCUMENT NUMBER: 97:127647
ORIGINAL REFERENCE NO.: 97:21193a,21196a
TITLE: Sulfones and their use
INVENTOR(S): Vamvakaris, Christos
PATENT ASSIGNEE(S): BASF A.-G. , Fed. Rep. Ger.
SOURCE: Eur. Pat. Appl., 32 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 50225	A1	19820428	EP 1981-107483		19810921
R: CH, DE, FR, GB, IT					
DE 3039208	A1	19820513	DE 1980-3039208		19801017
JP 57095957	A	19820615	JP 1981-164368		19811016

PRIORITY APPLN. INFO.: DE 1980-3039208 A 19801017
OTHER SOURCE(S): MARPAT 97:127647
IT 82651-67-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 82651-67-0 CAPLUS
CN Benzoxazole, 2-[2-[4-(5-phenyl-1,2,4-oxadiazol-3-yl)phenyl]-2-(phenylsulfonyl)ethyl]- (CA INDEX NAME)



L19 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:550674 CAPLUS
DOCUMENT NUMBER: 95:150674
ORIGINAL REFERENCE NO.: 95:25223a,25226a
TITLE: 1,2,4-Oxadiazole derivatives
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
JP 56065881	A	19810603	JP 1979-142540		19791101

PRIORITY APPLN. INFO.: JP 1979-142540 A 19791101
IT 79148-29-1P 79148-40-6P 79148-42-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 79148-29-1 CAPLUS
CN Benzeneacetic acid, α-methyl-4-[5-(4-methylphenyl)-1,2,4-oxadiazol-3-

yl]- (CA INDEX NAME)



RN 79148-40-6 CAPLUS
CN Benzeneacetic acid, 4-[5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl]-α-methyl- (CA INDEX NAME)



RN 79148-42-8 CAPLUS
CN Benzeneacetic acid, 4-[5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl]-α-methyl-, ethyl ester (CA INDEX NAME)



=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	67.77	1159.56

FILE 'STNGUIDE' ENTERED AT 18:05:50 ON 29 DEC 2008

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec 19, 2008 (20081219/UP).

=>